Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
Entera Bio priced an oversubscribed $275 million private placement at $2.04 per share, led by existing investor BVF Partners with participation from a syndicate of new healthcare-focused investors. The company intends to use the net proceeds to fully fund Phase 3 registrational studies for its lead asset EB613 and extend its cash runway into 2030.
Key figures
- Deal Value Usd
- 275000000
- Offering Price
- 2.04
- Shares Offered
- 122,961,215 ordinary shares + 11,842,695 pre-funded warrants
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.